Hui-Kuo George Shu MD
Professor, Radiation Oncology, Emory University School of Medicine
Join to View Full Profile
1365 Clifton Rd NeCT-104Atlanta, GA 30322
Phone+1 404-778-3473
Fax+1 404-778-3670
Dr. Shu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (San Francisco)Residency, Radiation Oncology, 1994 - 1999
Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Internal Medicine, 1993 - 1994
Case Western Reserve University School of MedicineClass of 1993
Certifications & Licensure
CA State Medical License 1995 - Present
GA State Medical License 2005 - 2027
NJ State Medical License 2002 - 2007
PA State Medical License 1999 - 2006
American Board of Radiology Radiation Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification FirstNet (Clinical), Cerner Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification HealtheLife and PowerChart, Cerner Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification P2 Sentinel, Cerner Corporation, 2014, 2016-2017
Clinical Trials
- Whole Brain Radiation Therapy With Boost to Metastatic Tumor Volume Using RapidArc Start of enrollment: 2010 Sep 22
- MRSI to Predict Response to RT/TMZ ± Belinostat in GBM Start of enrollment: 2014 May 07
- Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma Start of enrollment: 2017 Sep 20
Publications & Presentations
PubMed
- Long-Term Analysis of NRG Oncology RTOG 0539: A Phase II Trial of Observation for Low-Risk Meningioma and Radiotherapy for Intermediate- and High-Risk Meningioma.Rupesh Kotecha, Mei-Yin Polley, Michael A Vogelbaum, Arie Perry, Lynn Ashby
Journal of Clinical Oncology. 2026-05-27 - Modern Molecular Profiling Recontextualizes the NRG/RTOG 0539 Trial and Reveals Hidden High-Risk and Radiotherapy Resistant Meningiomas.Leeor S Yefet, Alexander P Landry, C Leland Rogers, Justin Z Wang, Jeff Liu
Neuro-Oncology. 2026-05-15 - An efficient 3D latent diffusion model for T1-contrast enhanced MRI generation.Zach Eidex, Mojtaba Safari, Jie Ding, Richard L J Qiu, Justin Roper
Biomedical Physics & Engineering Express. 2026-02-10
Journal Articles
- Fractionated Radiotherapy Is Associated with Lower Rates of Treatment-Related Edema Than Stereotactic Radiosurgery in MRI-Defined MeningiomasBree R Eaton, Ian R Crocker, Arif N Ali, Hui-Kuo G Shu, World Neurosurgery
Authored Content
- Does Size Matter? Investigating the Optimal Planning Target Volume Margin for Postoperative Stereotactic Radiosurgery to Resected Brain MetastasesApril 2018
- Does Size Matter? Investigating the Optimal Planning Target Volume Margin for Postoperative Stereotactic Radiosurgery to Resected Brain Metastases RelatedApril 2018
- Does Size Matter? Investigating the Optimal Planning Target Volume Margin for Postoperative Stereotactic Radiosurgery to Resected Brain Metastases RelatedApril 2018
Press Mentions
Advanced 3D MRI Technology Marks a Leap Forward in Glioblastoma ImagingMay 9th, 2016
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
